Guillain-Barré syndrome

The Lancet

Volumn 388, Issue 10045, 2016, Pages 717-727

  Willison, Hugh J ^a   Jacobs, Bart C ^b   van Doorn, Pieter A ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN ELECTROPHYSIOLOGY; CHRONIC INFLAMMATION; CLINICAL CLASSIFICATION; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); DEMYELINATING NEUROPATHY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOPATHOLOGY; INFECTION; MULTICENTER STUDY (TOPIC); NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; AXON; CAMPYLOBACTER JEJUNI; CAMPYLOBACTERIOSIS; COMPLICATION; DIFFERENTIAL DIAGNOSIS; DISEASE MANAGEMENT; ELECTROPHYSIOLOGY; GUILLAIN-BARRE SYNDROME; IMMUNOLOGY; MUSCLE WEAKNESS; NERVE CONDUCTION; PARALYSIS; PATHOLOGY; PLASMA EXCHANGE; PLASMAPHERESIS; PROGNOSIS; RESPIRATORY INSUFFICIENCY; TREATMENT OUTCOME;

IMMUNOGLOBULIN; INFLUENZA VACCINE;

AXONS; CAMPYLOBACTER INFECTIONS; CAMPYLOBACTER JEJUNI; CLINICAL TRIALS AS TOPIC; DIAGNOSIS, DIFFERENTIAL; DISEASE MANAGEMENT; ELECTROPHYSIOLOGY; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFLUENZA VACCINES; MUSCLE WEAKNESS; NEURAL CONDUCTION; PARALYSIS; PLASMA EXCHANGE; PLASMAPHERESIS; PROGNOSIS; RESPIRATORY INSUFFICIENCY; TREATMENT OUTCOME;

EID: 84961218834     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)00339-1     Document Type: Review

References (103)

1. 1 Asbury, AK, Cornblath, DR, Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 27:suppl (1990), S21–S24.
2. 2 Wakerley, BR, Yuki, N, Mimics and chameleons in Guillain-Barré and Miller Fisher syndromes. Pract Neurol 15 (2015), 90–99.
3. 3 Hughes, RA, Cornblath, DR, Guillain-Barré syndrome. Lancet 366 (2005), 1653–1666.
4. 4 van den Berg, B, Walgaard, C, Drenthen, J, Fokke, C, Jacobs, BC, van Doorn, PA, Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 10 (2014), 469–482.
5. 5 Willison, HJ, Goodyear, CS, Glycolipid antigens and autoantibodies in autoimmune neuropathies. Trends Immunol 34 (2013), 453–459.
6. 6 Blum, S, McCombe, PA, Genetics of Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): current knowledge and future directions. J Peripher Nerv Syst 19 (2014), 88–103.
7. 7 Huizinga, R, van den Berg, B, van Rijs, W, et al. Innate immunity to Campylobacter jejuni in Guillain-Barré syndrome. Ann Neurol 78 (2015), 343–354.
8. 8 Fokke, C, van den Berg, B, Drenthen, J, Walgaard, C, van Doorn, PA, Jacobs, BC, Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain 137 (2014), 33–43.
9. 9 Lim, JP, Devaux, J, Yuki, N, Peripheral nerve proteins as potential autoantigens in acute and chronic inflammatory demyelinating polyneuropathies. Autoimmun Rev 13 (2014), 1070–1078.
10. 10 Willison, HJ, Biomarkers in experimental models of antibody-mediated neuropathies. J Peripher Nerv Syst 16:suppl 1 (2011), 60–62.
11. 11 Hughes, RA, Wijdicks, EF, Benson, E, et al., for the Multidisciplinary Consensus Group. Supportive care for patients with Guillain-Barré syndrome. Arch Neurol 62 (2005), 1194–1198.
12. 12 Hughes, RA, Swan, AV, van Doorn, PA, Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev, 9, 2014 CD002063.
13. 13 Rajabally, YA, Uncini, A, Outcome and its predictors in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 83 (2012), 711–718.
14. 14 Walgaard, C, Lingsma, HF, Ruts, L, van Doorn, PA, Steyerberg, EW, Jacobs, BC, Early recognition of poor prognosis in Guillain-Barre syndrome. Neurology 76 (2011), 968–975.
15. 15 Sejvar, JJ, Baughman, AL, Wise, M, Morgan, OW, Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 36 (2011), 123–133.
16. 16 Webb, AJ, Brain, SA, Wood, R, Rinaldi, S, Turner, MR, Seasonal variation in Guillain-Barré syndrome: a systematic review, meta-analysis and Oxfordshire cohort study. J Neurol Neurosurg Psychiatry 86 (2015), 1196–1201.
17. 17 Huang, WC, Lu, CL, Chen, SC, A 15-year nationwide epidemiological analysis of Guillain-Barré syndrome in Taiwan. Neuroepidemiology 44 (2015), 249–254.
18. 18 Jackson, BR, Zegarra, JA, López-Gatell, H, et al., for the GBS Outbreak Investigation Team. Binational outbreak of Guillain-Barré syndrome associated with Campylobacter jejuni infection, Mexico and USA, 2011. Epidemiol Infect 142 (2014), 1089–1099.
19. 19 Geleijns, K, Brouwer, BA, Jacobs, BC, Houwing-Duistermaat, JJ, van Duijn, CM, van Doorn, PA, The occurrence of Guillain-Barré syndrome within families. Neurology 63 (2004), 1747–1750.
20. 20 Naik, KR, Saroja, AO, Patil, BP, Familial Guillain-Barré syndrome: first Indian report. Ann Indian Acad Neurol 15 (2012), 44–47.
21. 21 McCarthy, N, Andersson, Y, Jormanainen, V, Gustavsson, O, Giesecke, J, The risk of Guillain-Barré syndrome following infection with Campylobacter jejuni. Epidemiol Infect 122 (1999), 15–17.
22. 22 Jacobs, BC, Rothbarth, PH, van der Meché, FG, et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 51 (1998), 1110–1115.
23. 23 Islam, Z, Jacobs, BC, van Belkum, A, et al. Axonal variant of Guillain-Barre syndrome associated with Campylobacter infection in Bangladesh. Neurology 74 (2010), 581–587.
24. 24 Rees, JH, Soudain, SE, Gregson, NA, Hughes, RA, Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 333 (1995), 1374–1379.
25. 25 Mori, M, Kuwabara, S, Miyake, M, et al. Haemophilus influenzae infection and Guillain-Barré syndrome. Brain 123 (2000), 2171–2178.
26. 26 Geurtsvankessel, CH, Islam, Z, Mohammad, QD, Jacobs, BC, Endtz, HP, Osterhaus, AD, Hepatitis E and Guillain-Barre syndrome. Clin Infect Dis 57 (2013), 1369–1370.
27. 27 van den Berg, B, van der Eijk, AA, Pas, SD, et al. Guillain-Barré syndrome associated with preceding hepatitis E virus infection. Neurology 82 (2014), 491–497.
28. 28 Musso, D, Cao-Lormeau, VM, Gubler, DJ, Zika virus: following the path of dengue and chikungunya?. Lancet 386 (2015), 243–244.
29. 29 Ho, TW, Willison, HJ, Nachamkin, I, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol 45 (1999), 168–173.
30. 30 Jacobs, BC, van Doorn, PA, Schmitz, PI, et al. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol 40 (1996), 181–187.
31. 31 Schonberger, LB, Bregman, DJ, Sullivan-Bolyai, JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol 110 (1979), 105–123.
32. 32 Lehmann, HC, Hartung, HP, Kieseier, BC, Hughes, RA, Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis 10 (2010), 643–651.
33. 33 Salmon, DA, Proschan, M, Forshee, R, et al., for the H1N1 GBS Meta-Analysis Working Group. Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis. Lancet 381 (2013), 1461–1468.
34. 34 Guillain-Barré syndrome common concerns. http://www.cdc.gov/vaccinesafety/Concerns/gbs.html (accessed Feb 1, 2016).
35. 35 Kuitwaard, K, Bos-Eyssen, ME, Blomkwist-Markens, PH, van Doorn, PA, Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst 14 (2009), 310–315.
36. 36 Willison, HJ, The immunobiology of Guillain-Barré syndromes. J Peripher Nerv Syst 10 (2005), 94–112.
37. 37 Feasby, TE, Hahn, AF, Brown, WF, Bolton, CF, Gilbert, JJ, Koopman, WJ, Severe axonal degeneration in acute Guillain-Barré syndrome: evidence of two different mechanisms?. J Neurol Sci 116 (1993), 185–192.
38. 38 Willison, HJ, Yuki, N, Peripheral neuropathies and anti-glycolipid antibodies. Brain 125 (2002), 2591–2625.
39. 39 Koga, M, Ang, CW, Yuki, N, et al. Comparative study of preceding Campylobacter jejuni infection in Guillain-Barré syndrome in Japan and The Netherlands. J Neurol Neurosurg Psychiatry 70 (2001), 693–695.
40. 40 Soliven, B, Animal models of autoimmune neuropathy. ILAR J 54 (2014), 282–290.
41. 41 Susuki, K, Yuki, N, Schafer, DP, et al. Dysfunction of nodes of Ranvier: a mechanism for anti-ganglioside antibody-mediated neuropathies. Exp Neurol 233 (2012), 534–542.
42. 42 Willison, HJ, The translation of the pathological findings described in humans to experimental models of acute motor axonal neuropathy. J Peripher Nerv Syst 17:suppl 3 (2012), 3–8.
43. 43 Jacobs, BC, Koga, M, van Rijs, W, et al. Subclass IgG to motor gangliosides related to infection and clinical course in Guillain-Barré syndrome. J Neuroimmunol 194 (2008), 181–190.
44. 44 McGonigal, R, Rowan, EG, Greenshields, KN, et al. Anti-GD1a antibodies activate complement and calpain to injure distal motor nodes of Ranvier in mice. Brain 133 (2010), 1944–1960.
45. 45 Plomp, JJ, Willison, HJ, Pathophysiological actions of neuropathy-related anti-ganglioside antibodies at the neuromuscular junction. J Physiol 587 (2009), 3979–3999.
46. 46 Liu, JX, Willison, HJ, Pedrosa-Domellöf, F, Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest Ophthalmol Vis Sci 50 (2009), 3226–3232.
47. 47 Nachamkin, I, Liu, J, Li, M, et al. Campylobacter jejuni from patients with Guillain-Barré syndrome preferentially expresses a GD(1a)-like epitope. Infect Immun 70 (2002), 5299–5303.
48. 48 Makowska, A, Pritchard, J, Sanvito, L, et al. Immune responses to myelin proteins in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 79 (2008), 664–671.
49. 49 Willison, H, Scherer, SS, Ranvier revisited: novel nodal antigens stimulate interest in GBS pathogenesis. Neurology 83 (2014), 106–108.
50. 50 Sawai, S, Satoh, M, Mori, M, et al. Moesin is a possible target molecule for cytomegalovirus-related Guillain-Barré syndrome. Neurology 83 (2014), 113–117.
51. 51 Miyaji, K, Shahrizaila, N, Umapathi, T, Chan, YC, Hirata, K, Yuki, N, Are ERM (ezrin/radixin/moesin) proteins targets for autoantibodies in demyelinating neuropathies?. Hum Immunol 75 (2014), 1089–1091.
52. 52 Samukawa, M, Hamada, Y, Kuwahara, M, et al., for the Japanese GBS Study Group. Clinical features in Guillain-Barré syndrome with anti-Gal-C antibody. J Neurol Sci 337 (2014), 55–60.
53. 53 Kaida, K, Kusunoki, S, Immune-mediated neuropathy and anti-glycolipid antibodies. Brain Nerve 65 (2013), 413–423 (in Japanese).
54. 54 Chiba, A, Kusunoki, S, Obata, H, Machinami, R, Kanazawa, I, Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 43 (1993), 1911–1917.
55. 55 Kaida, K, Morita, D, Kanzaki, M, et al. Ganglioside complexes as new target antigens in Guillain-Barré syndrome. Ann Neurol 56 (2004), 567–571.
56. 56 Rinaldi, S, Brennan, KM, Kalna, G, et al. Antibodies to heteromeric glycolipid complexes in Guillain-Barré syndrome. PLoS One, 8, 2013, e82337.
57. 57 Galban-Horcajo, F, Halstead, SK, McGonigal, R, Willison, HJ, The application of glycosphingolipid arrays to autoantibody detection in neuroimmunological disorders. Curr Opin Chem Biol 18 (2014), 78–86.
58. 58 Hadden, RD, Cornblath, DR, Hughes, RA, et al., for the Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 44 (1998), 780–788.
59. 59 Umapathi, T, Tan, EY, Kokubun, N, Verma, K, Yuki, N, Non-demyelinating, reversible conduction failure in Fisher syndrome and related disorders. J Neurol Neurosurg Psychiatry 83 (2012), 941–948.
60. 60 Uncini, A, A common mechanism and a new categorization for anti-ganglioside antibody-mediated neuropathies. Exp Neurol 235 (2012), 513–516.
61. 61 Stathopoulos, P, Alexopoulos, H, Dalakas, MC, Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders. Nat Rev Neurol 11 (2015), 143–156.
62. 62 Uncini, A, Susuki, K, Yuki, N, Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies. Clin Neurophysiol 124 (2013), 1928–1934.
63. 63 Cashman, CR, Höke, A, Mechanisms of distal axonal degeneration in peripheral neuropathies. Neurosci Lett 596 (2015), 33–50.
64. 64 Kokubun, N, Nishibayashi, M, Uncini, A, Odaka, M, Hirata, K, Yuki, N, Conduction block in acute motor axonal neuropathy. Brain 133 (2010), 2897–2908.
65. 65 Sejvar, JJ, Kohl, KS, Gidudu, J, et al., for the Brighton Collaboration GBS Working Group. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 29 (2011), 599–612.
66. 66 van Doorn, PA, Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS). Presse Med 42 (2013), e193–e201.
67. 67 van den Berg, B, Fokke, C, Drenthen, J, van Doorn, PA, Jacobs, BC, Paraparetic Guillain-Barré syndrome. Neurology 82 (2014), 1984–1989.
68. 68 Ruts, L, Drenthen, J, Jongen, JL, et al., for the Dutch GBS Study Group. Pain in Guillain-Barre syndrome: a long-term follow-up study. Neurology 75 (2010), 1439–1447.
69. 69 Yuki, N, Kokubun, N, Kuwabara, S, et al. Guillain-Barré syndrome associated with normal or exaggerated tendon reflexes. J Neurol 259 (2012), 1181–1190.
70. 70 Oh, SJ, Kurokawa, K, de Almeida, DF, Ryan, HF Jr, Claussen, GC, Subacute inflammatory demyelinating polyneuropathy. Neurology 61 (2003), 1507–1512.
71. 71 Wong, AH, Umapathi, T, Nishimoto, Y, Wang, YZ, Chan, YC, Yuki, N, Cytoalbuminologic dissociation in Asian patients with Guillain-Barré and Miller Fisher syndromes. J Peripher Nerv Syst 20 (2015), 47–51.
72. 72 Yang, J, Huan, M, Jiang, H, Song, C, Zhong, L, Liang, Z, Pure sensory Guillain-Barré syndrome: a case report and review of the literature. Exp Ther Med 8 (2014), 1397–1401.
73. 73 Lyu, RK, Tang, LM, Cheng, SY, Hsu, WC, Chen, ST, Guillain-Barré syndrome in Taiwan: a clinical study of 167 patients. J Neurol Neurosurg Psychiatry 63 (1997), 494–500.
74. 74 Funakoshi, K, Kuwabara, S, Odaka, M, Hirata, K, Yuki, N, Clinical predictors of mechanical ventilation in Fisher/Guillain-Barré overlap syndrome. J Neurol Neurosurg Psychiatry 80 (2009), 60–64.
75. 75 Roodbol, J, de Wit, MC, Aarsen, FK, Catsman-Berrevoets, CE, Jacobs, BC, Long-term outcome of Guillain-Barré syndrome in children. J Peripher Nerv Syst 19 (2014), 121–126.
76. 76 Roodbol, J, de Wit, MC, Walgaard, C, de Hoog, M, Catsman-Berrevoets, CE, Jacobs, BC, Recognizing Guillain-Barre syndrome in preschool children. Neurology 76 (2011), 807–810.
77. 77 Ho, TW, Mishu, B, Li, CY, et al. Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain 118 (1995), 597–605.
78. 78 Vucic, S, Cairns, KD, Black, KR, Chong, PS, Cros, D, Neurophysiologic findings in early acute inflammatory demyelinating polyradiculoneuropathy. Clin Neurophysiol 115 (2004), 2329–2335.
79. 79 Kokubun, N, Shahrizaila, N, Hirata, K, Yuki, N, Reversible conduction failure is distinct from neurophysiological patterns of recovery in mild demyelinating Guillain-Barré syndrome. J Neurol Sci 326 (2013), 111–114.
80. 80 Uncini, A, Zappasodi, F, Notturno, F, Electrodiagnosis of GBS subtypes by a single study: not yet the squaring of the circle. J Neurol Neurosurg Psychiatry 86 (2015), 5–8.
81. 81 Walgaard, C, Lingsma, HF, Ruts, L, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol 67 (2010), 781–787.
82. 82 Liu, J, Wang, LN, McNicol, ED, Pharmacological treatment for pain in Guillain-Barré syndrome. Cochrane Database Syst Rev, 4, 2015 CD009950.
83. 83 Raphaël, JC, Chevret, S, Hughes, RA, Annane, D, Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev, 7, 2012 CD001798.
84. 84 Hughes, RA, Swan, AV, Raphael, JC, Annane, D, van Koningsveld, R, van Doorn, PA, Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 130 (2007), 2245–2257.
85. 85 Korinthenberg, R, Schessl, J, Kirschner, J, Mönting, JS, Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics 116 (2005), 8–14.
86. 86 Hughes, RA, van Doorn, PA, Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev, 8, 2012 CD001446.
87. 87 van Koningsveld, R, Schmitz, PI, Meché, FG, Visser, LH, Meulstee, J, van Doorn, PA, for the Dutch GBS study group. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 363 (2004), 192–196.
88. 88 Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 349 (1997), 225–230.
89. 89 Ruts, L, Drenthen, J, Jacobs, BC, van Doorn, PA, for the Dutch GBS Study Group. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology 74 (2010), 1680–1686.
90. 90 Fitzpatrick, AM, Mann, CA, Barry, S, Brennan, K, Overell, JR, Willison, HJ, An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst 16 (2011), 84–91.
91. 91 Halstead, SK, Zitman, FM, Humphreys, PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 131 (2008), 1197–1208.
92. 92 Kleyweg, RP, van der Meché, FG, Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry 54 (1991), 957–960.
93. 93 Dionne, A, Nicolle, MW, Hahn, AF, Clinical and electrophysiological parameters distinguishing acute-onset chronic inflammatory demyelinating polyneuropathy from acute inflammatory demyelinating polyneuropathy. Muscle Nerve 41 (2010), 202–207.
94. 94 Netto, AB, Taly, AB, Kulkarni, GB, Rao, UG, Rao, S, Mortality in mechanically ventilated patients of Guillain Barré Syndrome. Ann Indian Acad Neurol 14 (2011), 262–266.
95. 95 Benamer, HT, Bredan, A, Guillain-Barré syndrome in Arab countries: a systematic review. J Neurol Sci 343 (2014), 221–223.
96. 96 van den Berg, B, Bunschoten, C, van Doorn, PA, Jacobs, BC, Mortality in Guillain-Barre syndrome. Neurology 80 (2013), 1650–1654.
97. 97 Darweesh, SK, Polinder, S, Mulder, MJ, et al. Health-related quality of life in Guillain-Barré syndrome patients: a systematic review. J Peripher Nerv Syst 19 (2014), 24–35.
98. 98 Drenthen, J, Jacobs, BC, Maathuis, EM, van Doorn, PA, Visser, GH, Blok, JH, Residual fatigue in Guillain-Barre syndrome is related to axonal loss. Neurology 81 (2013), 1827–1831.
99. 99 Merkies, IS, Faber, CG, Fatigue in immune-mediated neuropathies. Neuromuscul Disord 22:suppl 3 (2012), S203–S207.
100. 100 Bernsen, RA, de Jager, AE, Schmitz, PI, van der Meché, FG, Residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome. Neurology 53 (1999), 409–410.
101. 101 Vanhoutte, EK, Faber, CG, Merkies, IS, for the PeriNomS study group. 196th ENMC international workshop: outcome measures in inflammatory peripheral neuropathies 8–10 February 2013, Naarden, The Netherlands. Neuromuscul Disord 23 (2013), 924–933.
102. 102 van Koningsveld, R, Steyerberg, EW, Hughes, RA, Swan, AV, van Doorn, PA, Jacobs, BC, A clinical prognostic scoring system for Guillain-Barré syndrome. Lancet Neurol 6 (2007), 589–594.
103. 103 Yuki, N, Hartung, HP, Guillain-Barré syndrome. N Engl J Med 366 (2012), 2294–2304.